HOSPITAL UNIVERSITARIO RUBER
Saila
University of the Witwatersrand
Johannesburgo, SudáfricaUniversity of the Witwatersrand-ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2023
-
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
The Lancet Child and Adolescent Health, Vol. 7, Núm. 3, pp. 180-189
2022
-
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
New England Journal of Medicine